Kaise R, Hirota F, Sakamoto K, Suminaga M, Sato S, Karibe M, Nagai K, Mugitani H, Kako M, Furue H
Gan To Kagaku Ryoho. 1987 Mar;14(3 Pt 2):896-902.
Interferon production in vitro was induced by poly I: C and PHA in leukocytes obtained from patients with cancer, benign diseases and control subjects. The interferon response per lymphocyte was relatively constant in all groups. However, interferon production was slightly inhibited in patients receiving cancer chemotherapy. The peak response of interferon occurred at 48 hours after the initiation of the combined culture in each specimen. From our observations, it was suggested that interferon production in vitro seems to be useful marker for evaluation of effect of chemotherapy and or immunotherapy, and, furthermore, in the treatment of cancer patients with interferon inducers, there seems to be optimum BRM dose and optimum timing of administration.
聚胞苷酸（poly I:C）和植物血凝素（PHA）在从癌症患者、良性疾病患者及对照受试者获取的白细胞中诱导体外干扰素产生。每组中每个淋巴细胞的干扰素反应相对恒定。然而，接受癌症化疗的患者中干扰素产生略有抑制。每个标本在联合培养开始后48小时出现干扰素的峰值反应。根据我们的观察结果，提示体外干扰素产生似乎是评估化疗和/或免疫治疗效果的有用标志物，此外，在用干扰素诱导剂治疗癌症患者时，似乎存在最佳生物反应调节剂（BRM）剂量和最佳给药时机。
